EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

FcRn-guided antigen trafficking enhances cancer vaccine efficacy

Mengyu Hong, Muziying Liu, Fang Zhu, Dan Zhao, Guilai Liu, Tiyun Han, Caiyi Fei, Weihong Zeng, Shi Chen, Qiqin Wu, Bofeng Li, Songquan Wu und 5 weitere

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-024-03888-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Mengyu Hong und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Center for Advanced Interdisciplinary Science and Biomedicine of IHM,…. Hauptthemen laut MEDLINE: Histocompatibility Antigens Class I, Cancer Vaccines, Receptors, Fc, Antigen Presentation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, the National Key Research and Development Program of China, the Strategic Priority Research Program of the Chinese Academy of Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of tumor vaccines represents a significant focus within cancer therapeutics research. Nonetheless, the efficiency of antigen presentation in tumor vaccine remains suboptimal. We introduce an innovative mRNA-lipid nanoparticle platform designed to express tumor antigenic epitopes fused with the transmembrane domain and cytoplasmic tail of the neonatal Fc receptor (FcRn). This novel design exploits FcRn trafficking signals to direct the epitope-FcRn fusion toward endolysosomal degradation, thereby generating epitopes capable of eliciting targeted T cell responses and establishing immune memory. The FcRn-directed presentation of epitopes enhances MHC class I and II antigen presentation, thereby robustly inducing CD4+ and CD8+ T cell responses, which translates to the inhibition of tumor growth and extension of survival in preclinical mouse models. In summary, the deliberate incorporation of FcRn trafficking signals into vaccine design markedly boosts T cell responses, underscoring the promise of this novel strategy in advancing the efficacy of tumor vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histocompatibility Antigens Class ICancer VaccinesReceptors, FcAntigen PresentationAnimalsMiceHumansAntigens, NeoplasmMice, Inbred C57BLNanoparticlesCD8-Positive T-LymphocytesFemaleCell Line, TumorNeoplasmsLiposomes

Stichwörter der Autor:innen

Antigen presentationFcRnT cell epitopeTumormRNA vaccine

Substanzen

Histocompatibility Antigens Class ICancer VaccinesFc receptor, neonatalReceptors, FcAntigens, NeoplasmLipid NanoparticlesLiposomes

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Tec…
  • Laboratory of Structural Immunology, Key Laboratory of Immune Response and Immunotherapy, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230027, China.
  • Therarna. Co. Ltd., Nanjing, 210000, Jiangsu, China.
  • Anhui Genebiol Biotech. LTD., Hefei, 230000, China.
  • College of Medicine, Lishui University, Lishui, 323000, China.
  • Department of Breast Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230031, Anhui, China. zhoushoubingseu@126.com.

Förderung

  • National Key Research and Development Program of China
  • the National Key Research and Development Program of China
  • the Strategic Priority Research Program of the Chinese Academy of Sciences
  • the National Natural Science Foundation of China
  • the Anhui Provincial Key Research and Development Project
  • the Fundamental Research Funds for the Central Universities

Zitieren

APA

Hong, M., Liu, M., Zhu, F., Zhao, D., Liu, G., Han, T., Fei, C., Zeng, W., Chen, S., Wu, Q., Li, B., Wu, S., Shang, Y., Ma, H., Zhou, S., Xu, S., & Jin, T. (2025). FcRn-guided antigen trafficking enhances cancer vaccine efficacy. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03888-y

Vancouver

Hong M, Liu M, Zhu F, Zhao D, Liu G, Han T, et al. FcRn-guided antigen trafficking enhances cancer vaccine efficacy. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-024-03888-y

BibTeX
@article{Hong2025,
  author = {Hong, Mengyu and Liu, Muziying and Zhu, Fang and Zhao, Dan and Liu, Guilai and Han, Tiyun and Fei, Caiyi and Zeng, Weihong and Chen, Shi and Wu, Qiqin and Li, Bofeng and Wu, Songquan and Shang, Yuhua and Ma, Huan and Zhou, Shoubing and Xu, Shi and Jin, Tengchuan},
  title = {FcRn-guided antigen trafficking enhances cancer vaccine efficacy},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-024-03888-y}
}
Kostenlos starten →